Artios Pharma Limited has closed an oversubscribed $115 million Series D financing to accelerate clinical development across its portfolio of DNA damage response therapeutics. The round was co-led by SV Health Investors and RA Capital Management, with participation from Janus Henderson Investors and strong support from existing backers.
The new capital will expand clinical evaluation of alnodesertib, Artios’ ATR inhibitor, across additional ATM-negative patient cohorts in second-line pancreatic cancer and third-line colorectal cancer. Alnodesertib recently received Fast Track Designation from the U.S. FDA and delivered a confirmed overall response rate of 50 percent when combined with low-dose irinotecan in ATM-negative solid tumors in the STELLA Phase 1/2a trial presented at AACR earlier this year. No approved therapies currently exist for patients whose tumors harbor ATM deficiency, despite meaningful clinical need across multiple tumor types.
Proceeds from the Series D will also support a randomized Phase 2 study of ART6043, Artios’ Polθ inhibitor, in BRCA-mutant HER2-negative breast cancer patients eligible for PARP inhibitor therapy. Data presented at the 2025 ESMO Congress showed favorable tolerability, expected PK and PD activity, and early signals of clinical benefit. Artios is additionally advancing a first-in-class DDR inhibitor–ADC program and plans to announce a lead candidate in the first quarter of 2026.
The financing follows a period of strategic momentum for the company as it advances two potential first-in-class clinical programs, prepares late-stage development plans, and strengthens its position within the competitive DDR therapeutic landscape. Investor participation reflects deepening confidence in Artios’ scientific foundation, clinical data, and expanding commercial potential.
The Series D round included participation from Andera Partners, Avidity Partners, EQT Life Sciences, Invus, IP Group plc, Janus Henderson Investors, M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures, Piper Heartland, RA Capital Management, Schroders Capital, Sofinnova Partners, and SV Health Investors.
Artios continues to build a comprehensive portfolio of next-generation DDR oncology medicines enabled by a team with extensive expertise in the field. Its programs aim to target cancer cell survival pathways precisely and address patient populations with limited treatment options.
KEY QUOTES
“This Series D accelerates our potential path to registration for both alnodesertib and ART6043, broadening development for the next generation of DNA damage response (DDR) therapeutics to indications among the highest of unmet need across pancreatic, colorectal, and breast cancers, where median survival is often measured in months. As we address these indications and prepare for others, I would like to thank our existing investors, led by SV Health, for their ongoing support, and also our new investors, RA Capital Management and Janus Henderson Investors, for joining our mission to bring these potential medicines to patients as quickly as possible.”
Mike Andriole, Chief Executive Officer, Artios
“We are thrilled to have supported Artios’ evolution, from an early-stage DDR pioneer when we founded the company to the established company it has become, distinguished by a promising and differentiated pipeline. We look forward to continuing to do so as it deploys the Series D proceeds to drive late-stage development of alnodesertib as well as its pipeline. This financing, and the recent appointment of Mike Andriole as CEO, are exciting steps in Artios’ continued growth and its transition toward becoming a commercially oriented organization.”
Nikola Trbovic, Managing Partner, SV Health Investors
“We are excited to co-lead this financing round to advance the next generation of DNA damage response therapeutics. Artios’ differentiated clinical programs, alnodesertib and ART6043, together have the potential to meaningfully expand the impact of DDR-targeted therapies. The rate and durability of responses observed to date for alnodesertib across a range of solid tumors and the early clinical results with ART6043 underscore the strength of Artios’ approach and ability to deliver novel, potentially first-in-class treatments for patients while building significant long-term value.”
Jake Simson, Partner, RA Capital Management
